Chinese Academy of Medical Sciences

Institute of Medical Biology, Cams

Dandan Li

Ying Zhang

Heng Li

Huiwen Zheng

Yun Liao

Haijing Shi

Heng Zhao

Longding Liu

Guorun Jiang

Li Yu

Xin Zhao

Provided is a Coxsackievirus A6 (CVA6) strain CVA6-KM-J33 and use thereof, and belongs to the technical field of biomedicine. The present invention provides a CVA6 strain CVA6-KM-J33, which belongs to a CVA6 virus. In the present invention, the strain CVA6-KM-J33 is susceptible to KMB17 cells and can achieve a relatively high titer. The strain has strong virulence, high pathogenicity and lethality to suckling mice, and desirable immunogenicity, and is a highly effective virus strain for CVA6 vaccine development. This strain can be used for immunogenicity evaluation or protective evaluation of CVA6 vaccine to improve the accuracy and reproducibility of vaccine immunogenicity evaluation. This strain can also be used to prepare animal models of Coxsackievirus (CV) infection, and exhibits desirable application prospects.

Coxsackievirus A6 strain CVA6-KM-J33 and use thereof

An enterovirus multi-antigen epitope fusion protein, a gene, a vaccine and a preparation method thereof are provided, relating to the field of vaccine preparation technologies. The amino acid sequence of the enterovirus multi-antigen epitope fusion protein is shown in SEQ ID NO: 4. The vaccine is prepared by adopting the preparation method of a genetically engineered protein vaccine, and the prepared vaccine has stronger specificity. After protein purification, there are fewer impure proteins and more specific antigen proteins, thus improving the effectiveness and safety of the combined vaccine.

Enterovirus multi-antigen epitope fusion protein, gene, vaccine, and preparation method thereof

Growing community of inventors

Kunming, China

Dandan Li